Au8, an experimental ALS therapy. CNM-Au8 has been associated with NfL reductions, a biomarker finding linked to longer ...

High-dose dazucorilant showed significant survival benefit in a Phase 2 ALS trial. It reduced mortality risk by up to 87% over two years for ALS patients. A pivotal Phase 3 trial for this ALS therapy ...

May is ALS Awareness Month, and in the U.S. and around the world, organizations are educating, sponsoring events, and encouraging the community to join them in taking action, providing financial ...

PIONEER-ALS, a clinical trial evaluating VTx-002 as a treatment for ALS, has been given a green light to launch study sites in three European nations. The therapy targets toxic TDP-43 protein clumps, ...

ALS creates a significant financial burden for French families despite full heathcare coverage. Families face thousands in out-of-pocket costs. Caregivers often stop working, which adds to the ...

The data cover the first part of an ongoing Phase 1/2 clinical trial (NCT06556394), in which participants received a single injection of RAG-17 at doses ranging from 30-180 mg, or ...

ALS death rates in Finland nearly doubled between 1987 and 2022, especially in older adults, a study found. Researchers noted that this trend has not been observed in other countries, such as the U.S.

In the early, scary months after my late husband, Jeff, was diagnosed with ALS in the fall of 2018, I started to realize that ...

The MDA Wings Over Wall Street Gala raises funds for ALS research. The event unites financial and medical communities to find a cure. More than $13 million has been raised since 2000, driving research ...